Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

According to the Australian Dyslexia Association, “Dyslexia is estimated to affect some 10% of the Australian population.” This squarely puts...

European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline...

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt...

A Changing Landscape The emergence of mobile technology, social media, and high-speed internet has democratized live reporting, allowing...

While AEM is well-placed on a strong pipeline of growth projects, solid financial health and a healthy growth trajectory, its high costs warrant...

While AEM is well-placed on a strong pipeline of growth projects, solid financial health and a healthy growth trajectory, its high costs warrant...

The Ministry of Health has officially launched Kenya’s first Clinical Guidelines for the Management of Common Mental Disorders, along with a...

WEDNESDAY, Sept. 11, 2024 -- Weekly insulin shots can help control both type 1 and type 2 diabetes as well as daily injections do, a pair of clinical...